At the mRNA level PSMA-coding gene FOLH1 (folate hydrolase 1) expression is to a certain extent detectable almost in all tumor types, however, there are several spikes on this pan-tumor landscape where the potential diagnostic and therapeutic applications of PSMA seems to be more promising, even if the expression in comparison to prostate cancer is relatively low (Figure 1). This evidence concerns the gene FOLH1 and prostate cancer.